New human CD22/siglec-2 ligands with a triazole glycoside
CD22 is a member of the Siglec family. Considerable attention has been drawn to the design and synthesis of new Siglec ligands to explore target biology and innovative therapies. In particular, CD22-ligand-targeted nanoparticles with therapeutic functions have proved successful in preclinical settin...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
04 April 2017
|
| In: |
ChemBioChem
Year: 2017, Jahrgang: 18, Heft: 13, Pages: 1216-1225 |
| ISSN: | 1439-7633 |
| DOI: | 10.1002/cbic.201600707 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1002/cbic.201600707 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/cbic.201600707 
|
| Verfasserangaben: | Horst Prescher, Astrid Schweizer, Elena Kuhfeldt, Lars Nitschke, and Reinhard Brossmer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1581224508 | ||
| 003 | DE-627 | ||
| 005 | 20220815015305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180924s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cbic.201600707 |2 doi | |
| 035 | |a (DE-627)1581224508 | ||
| 035 | |a (DE-576)511224508 | ||
| 035 | |a (DE-599)BSZ511224508 | ||
| 035 | |a (OCoLC)1341019159 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 32 |2 sdnb | ||
| 100 | 1 | |a Prescher, Horst |e VerfasserIn |0 (DE-588)1167703855 |0 (DE-627)1031226583 |0 (DE-576)511220758 |4 aut | |
| 245 | 1 | 0 | |a New human CD22/siglec-2 ligands with a triazole glycoside |c Horst Prescher, Astrid Schweizer, Elena Kuhfeldt, Lars Nitschke, and Reinhard Brossmer |
| 264 | 1 | |c 04 April 2017 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 24.09.2018 | ||
| 520 | |a CD22 is a member of the Siglec family. Considerable attention has been drawn to the design and synthesis of new Siglec ligands to explore target biology and innovative therapies. In particular, CD22-ligand-targeted nanoparticles with therapeutic functions have proved successful in preclinical settings for blood cancers, autoimmune diseases, and tolerance induction. Here we report the design, synthesis and affinity evaluation of a new class of Siglec ligands: namely sialic acid derivatives with a triazole moiety replacing the natural glycoside oxygen atom. In addition, we describe important and surprising differences in binding to CD22 expressed at the cell surface for compounds with distinct valences. The new class of compounds might serve as a template for the design of ligands for other members of the Siglec family and next-generation CD22-ligand-based targeted therapies. | ||
| 650 | 4 | |a carbohydrates | |
| 650 | 4 | |a drug design | |
| 650 | 4 | |a drug discovery | |
| 650 | 4 | |a sialic acids | |
| 650 | 4 | |a structure-activity relationships | |
| 700 | 1 | |a Brossmer, Reinhard |d 1925-2020 |e VerfasserIn |0 (DE-588)1115343556 |0 (DE-627)869722298 |0 (DE-576)324407076 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ChemBioChem |d Weinheim : Wiley-VCH, 2000 |g 18(2017), 13, Seite 1216-1225 |h Online-Ressource |w (DE-627)320603539 |w (DE-600)2020469-3 |w (DE-576)091208505 |x 1439-7633 |7 nnas |a New human CD22/siglec-2 ligands with a triazole glycoside |
| 773 | 1 | 8 | |g volume:18 |g year:2017 |g number:13 |g pages:1216-1225 |g extent:10 |a New human CD22/siglec-2 ligands with a triazole glycoside |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cbic.201600707 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/cbic.201600707 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180924 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1115343556 |a Brossmer, Reinhard |m 1115343556:Brossmer, Reinhard |d 700000 |d 711000 |e 700000PB1115343556 |e 711000PB1115343556 |k 0/700000/ |k 1/700000/711000/ |p 5 |y j | ||
| 999 | |a KXP-PPN1581224508 |e 3026369713 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Horst Prescher, Astrid Schweizer, Elena Kuhfeldt, Lars Nitschke, and Reinhard Brossmer"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"04 April 2017"}],"id":{"doi":["10.1002/cbic.201600707"],"eki":["1581224508"]},"physDesc":[{"extent":"10 S."}],"relHost":[{"title":[{"title_sort":"ChemBioChem","subtitle":"an official journal of the EFMC","title":"ChemBioChem"}],"titleAlt":[{"title":"a European journal of chemical biology"}],"part":{"text":"18(2017), 13, Seite 1216-1225","volume":"18","extent":"10","year":"2017","issue":"13","pages":"1216-1225"},"pubHistory":["1.2000,1 (July) -"],"recId":"320603539","language":["eng"],"disp":"New human CD22/siglec-2 ligands with a triazole glycosideChemBioChem","note":["Fortsetzung der Druck-Ausgabe","Gesehen am 10.11.2022"],"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"issn":["1439-7633"],"doi":["10.1002/(ISSN)1439-7633"],"eki":["320603539"],"zdb":["2020469-3"]},"origin":[{"publisherPlace":"Weinheim","publisher":"Wiley-VCH","dateIssuedDisp":"[2000]-"}],"name":{"displayForm":["European Federation for Medicinal chemistry and Chemical biology"]},"physDesc":[{"extent":"Online-Ressource"}]}],"person":[{"family":"Prescher","given":"Horst","display":"Prescher, Horst","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Reinhard","family":"Brossmer","role":"aut","roleDisplay":"VerfasserIn","display":"Brossmer, Reinhard"}],"title":[{"title_sort":"New human CD22/siglec-2 ligands with a triazole glycoside","title":"New human CD22/siglec-2 ligands with a triazole glycoside"}],"note":["Gesehen am 24.09.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1581224508","language":["eng"]} | ||
| SRT | |a PRESCHERHONEWHUMANCD0420 | ||